Skip to main content
Premium Trial:

Request an Annual Quote

Sysmex Inostics Inks OncoBEAM Distribution Deal with IndivuTest

NEW YORK (GenomeWeb) – Sysmex Inostics today announced that it has signed an exclusive distribution agreement with IndivuTest for the OncoBEAM test.

Under the terms of the agreement, IndivuTest will offer Sysmex Inostics' OncoBEAM laboratory-based test throughout Germany, Austria, and Switzerland. IndivuTest will be responsible for commercial and sample logistics, while Sysmex Inostics will perform all testing services at its CLIA laboratory in Baltimore.

The OncoBEAM services analyze a wide range of clinically actionable genetic mutations in cell-free tumor DNA from blood or plasma to inform cancer treatment decisions, the firm said in a statement.

Financial details of the agreement were not disclosed.

In 2013 Japanese in vitro diagnostics firm Sysmex acquired Inostics from IndivuTest's parent company, Indivumed.

The Scan

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.

Using Bees to Gain Insights into Urban Microbiomes

As bees buzz around, they pick up debris that provides insight into the metagenome of their surroundings, researchers report in Environmental Microbiome.

Age, Genetic Risk Tied to Blood Lipid Changes in New Study

A study appearing in JAMA Network Open suggests strategies to address high lipid levels should focus on individuals with high genetic risk and at specific ages.